These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 20039183)

  • 1. Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.
    Russell AS; Olszynski WP; Davison KS; Koehn C; Haraoui B
    Clin Rheumatol; 2010 Mar; 29(3):233-9. PubMed ID: 20039183
    [No Abstract]   [Full Text] [Related]  

  • 2. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy.
    Caporali R; Conti F; Alivernini S; Atzeni F; Seriolo B; Cutolo M; Valesini G; Ferraccioli G; Sarzi-Puttini P; Salvarani C; Guiducci S; Zampogna G; Gremese E; Pipitone N; Scrivo R; Bugatti S; Montecucco C; Matucci-Cerinic M;
    Clin Exp Rheumatol; 2011; 29(3 Suppl 66):S7-14. PubMed ID: 21906423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety.
    Favalli EG; Caporali R; Sinigaglia L; Pipitone N; Miniati I; Montecucco C; Matucci-Cerinic M;
    Clin Exp Rheumatol; 2011; 29(3 Suppl 66):S15-27. PubMed ID: 21906424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Proposal for biologic drugs therapy in rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S
    Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statement of the German Society of Rheumatology (DGRh) reporting on the Institute's plan for biologicals in the second-line therapy for rheumatoid arthritis].
    Braun J; Krüger K; Genth E
    Z Rheumatol; 2011 Dec; 70(10):882-3. PubMed ID: 22139207
    [No Abstract]   [Full Text] [Related]  

  • 6. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
    Singh JA; Saag KG; Bridges SL; Akl EA; Bannuru RR; Sullivan MC; Vaysbrot E; McNaughton C; Osani M; Shmerling RH; Curtis JR; Furst DE; Parks D; Kavanaugh A; O'Dell J; King C; Leong A; Matteson EL; Schousboe JT; Drevlow B; Ginsberg S; Grober J; St Clair EW; Tindall E; Miller AS; McAlindon T;
    Arthritis Care Res (Hoboken); 2016 Jan; 68(1):1-25. PubMed ID: 26545825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).
    Deighton CM; George E; Kiely PD; Ledingham J; Luqmani RA; Scott DG
    Rheumatology (Oxford); 2006 Jun; 45(6):649-52. PubMed ID: 16527881
    [No Abstract]   [Full Text] [Related]  

  • 8. Patient access to rheumatoid arthritis treatments.
    Jönsson B; Kobelt G; Smolen J
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S33-4. PubMed ID: 18097698
    [No Abstract]   [Full Text] [Related]  

  • 9. Rheumatoid arthritis: 2011 remission criteria are a new benchmark for RA therapy.
    Bykerk VP
    Nat Rev Rheumatol; 2011 Jun; 7(6):317-8. PubMed ID: 21556029
    [No Abstract]   [Full Text] [Related]  

  • 10. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.
    Sanmartí R; García-Rodríguez S; Álvaro-Gracia JM; Andreu JL; Balsa A; Cáliz R; Fernández-Nebro A; Ferraz-Amaro I; Gómez-Reino JJ; González-Álvaro I; Martín-Mola E; Martínez-Taboada VM; Ortiz AM; Tornero J; Marsal S; Moreno-Muelas JV
    Reumatol Clin; 2015; 11(5):279-94. PubMed ID: 26051464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The case against haste in the treatment of rheumatoid arthritis: comment on the editorial by Pincus et al.
    Epstein WV
    Arthritis Rheum; 2003 Feb; 48(2):573-5; author reply 576-9. PubMed ID: 12571870
    [No Abstract]   [Full Text] [Related]  

  • 12. Achievement of NICE quality standards for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.
    Ledingham JM; Snowden N; Rivett A; Galloway J; Ide Z; Firth J; MacPhie E; Kandala N; Dennison EM; Rowe I
    Rheumatology (Oxford); 2017 Feb; 56(2):223-230. PubMed ID: 27694337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognosis for rheumatoid arthritis].
    Ostendorf GM
    Versicherungsmedizin; 2015 Mar; 67(1):36. PubMed ID: 25971151
    [No Abstract]   [Full Text] [Related]  

  • 14. Shouldn't standard rheumatology clinical care be evidence-based rather than eminence-based, eloquence-based, or elegance-based?
    Pincus T; Tugwell P
    J Rheumatol; 2007 Jan; 34(1):1-4. PubMed ID: 17216670
    [No Abstract]   [Full Text] [Related]  

  • 15. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Louthrenoo W; Kasitanon N; Katchamart W; Aiewruengsurat D; Chevaisrakul P; Chiowchanwisawakit P; Dechanuwong P; Hanvivadhanakul P; Mahakkanukrauh A; Manavathongchai S; Muangchan C; Narongroeknawin P; Phumethum V; Siripaitoon B; Suesuwan A; Suwannaroj S; Uea-Areewongsa P; Ukritchon S; Asavatanabodee P; Koolvisoot A; Nanagara R; Totemchokchyakarn K; Nuntirooj K; Kitumnuaypong T
    Int J Rheum Dis; 2017 Sep; 20(9):1166-1184. PubMed ID: 28730640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hotel-based rheumatology, and more.
    Leeb BF
    J Rheumatol; 2009 Feb; 36(2):455-6; author reply 456-7. PubMed ID: 19208582
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal treatment of rheumatoid arthritis: EULAR recommendations for clinical practice.
    Bijlsma JW
    Pol Arch Med Wewn; 2010 Sep; 120(9):347-53. PubMed ID: 20864908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis.
    Lau CS; Chia F; Dans L; Harrison A; Hsieh TY; Jain R; Jung SM; Kishimoto M; Kumar A; Leong KP; Li Z; Lichauco JJ; Louthrenoo W; Luo SF; Mu R; Nash P; Ng CT; Suryana B; Wijaya LK; Yeap SS
    Int J Rheum Dis; 2019 Mar; 22(3):357-375. PubMed ID: 30809944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The burden of rheumatoid arthritis and access to treatment: determinants of access.
    Lundqvist J; Kastäng F; Kobelt G; Jönsson B
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S87-93. PubMed ID: 18157560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of prognostic markets to guide biologic therapies for rheumatoid arthritis.
    D'Arcy CA; Willkens RF
    J Rheumatol; 2002 Dec; 29(12):2662; author reply 2662-3. PubMed ID: 12465172
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.